According to a recent LinkedIn post from BioInnovation Institute, the organization is promoting applications for its Upscalator program, which close on September 1. The post indicates that Upscalator, funded by Novo Nordisk Foundation and operated by BII, provides convertible loans to support collaborations with contract development and manufacturing organizations.
The LinkedIn post highlights that Upscalator is designed to help biosolutions startups move from lab-scale development to industrial production. In addition to funding, the program reportedly offers expert guidance on fermentation and process development, access to specialized facilities, a network of service providers, and a peer community focused on scale-up challenges.
As referenced in the post, the initiative builds on a pilot project with NorFalk, which used Upscalator support to advance from lab to pilot scale. The pilot is described as having strengthened NorFalk’s market position, increased customer interest, advanced commercial discussions, and helped attract investor attention, suggesting potential proof-of-concept for the program’s impact.
For investors, the post suggests that BII is deepening its role as an enabler of early-stage industrial biosolutions, which could enhance deal flow and de-risk scale-up for portfolio companies. The focus on CDMO collaboration and process development infrastructure may position BII as a strategic hub in the bioindustrial ecosystem, potentially improving the commercialization prospects of startups it supports and increasing the attractiveness of the broader BII-backed pipeline.